* Juno Therapeutics presents data from TRANSCEND study
showing 60% complete response in patients with relapsed or
refractory aggressive CD19+ non-hodgkin lymphoma
The post BRIEF-Juno therapeutics presents data from TRANSCEND study appeared first on NASDAQ.